Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms21186595 http://scihub22266oqcxt.onion/10.3390/ijms21186595 32916926!7555114!32916926     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Mol+Sci 2020 ; 21 (18): ä Nephropedia Template TP {{tp|p=32916926|t=2020. Improved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based Antibody Assay |pdf=|usr=}}{{32916926}} gab.com Text Improved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based Antibody Assay JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32916926 #FOAvip Currently available COVID-19 antibody tests using enzyme immunoassay (EIA) or immunochromatographic assay have variable sensitivity and specificity. Here, we developed and evaluated a novel microsphere-based antibody assay (MBA) for detecting immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein (NP) and spike protein receptor binding domain (RBD). The seropositive cutoff value was set using a cohort of 294 anonymous serum specimens collected in 2018. The specificity was assessed using serum specimens collected from organ donors or influenza patients before 2020. Seropositive rate was determined among COVID-19 patients. Time-to-seropositivity and signal-to-cutoff (S/CO) ratio were compared between MBA and EIA. MBA had a specificity of 100% (93/93; 95% confidence interval (CI), 96-100%) for anti-NP IgG, 98.9% (92/93; 95% CI 94.2-100%) for anti-RBD IgG. The MBA seropositive rate for convalescent COVID-19 patients was 89.8% (35/39) for anti-NP IgG and 79.5% (31/39) for anti-RBD IgG. The time-to-seropositivity was shorter with MBA than EIA. MBA could better differentiate between COVID-19 patients and negative controls with higher S/CO ratio for COVID-19 patients, lower S/CO ratio with negative controls and fewer specimens in the equivocal range. MBA is robust, simple and is suitable for clinical microbiology laboratory for the accurate determination of anti-SARS-CoV-2 antibodies for diagnosis, serosurveillance, and vaccine trials. Twit Text FOAVip Improved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based Antibody Assay ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32916926 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32916926 #FOAvip English Wikipedia <ref>{{Cite pmid|32916926}}</ref> Improved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based Antibody Assay #MMPMID32916926 Fong CH; Cai JP; Dissanayake TK; Chen LL; Choi CY; Wong LH; Ng AC; Pang PKP; Ho DT; Poon RW; Chung TW; Sridhar S; Chan KH; Chan JF; Hung IF; Yuen KY; To KK Int J Mol Sci 2020[Sep]; 21 (18): ä PMID32916926show ga Currently available COVID-19 antibody tests using enzyme immunoassay (EIA) or immunochromatographic assay have variable sensitivity and specificity. Here, we developed and evaluated a novel microsphere-based antibody assay (MBA) for detecting immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein (NP) and spike protein receptor binding domain (RBD). The seropositive cutoff value was set using a cohort of 294 anonymous serum specimens collected in 2018. The specificity was assessed using serum specimens collected from organ donors or influenza patients before 2020. Seropositive rate was determined among COVID-19 patients. Time-to-seropositivity and signal-to-cutoff (S/CO) ratio were compared between MBA and EIA. MBA had a specificity of 100% (93/93; 95% confidence interval (CI), 96-100%) for anti-NP IgG, 98.9% (92/93; 95% CI 94.2-100%) for anti-RBD IgG. The MBA seropositive rate for convalescent COVID-19 patients was 89.8% (35/39) for anti-NP IgG and 79.5% (31/39) for anti-RBD IgG. The time-to-seropositivity was shorter with MBA than EIA. MBA could better differentiate between COVID-19 patients and negative controls with higher S/CO ratio for COVID-19 patients, lower S/CO ratio with negative controls and fewer specimens in the equivocal range. MBA is robust, simple and is suitable for clinical microbiology laboratory for the accurate determination of anti-SARS-CoV-2 antibodies for diagnosis, serosurveillance, and vaccine trials. |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Viral/*blood/immunology[MESH] |COVID-19[MESH] |Child[MESH] |Child, Preschool[MESH] |Coronavirus Infections/*blood/diagnosis[MESH] |Coronavirus Nucleocapsid Proteins[MESH] |Female[MESH] |Humans[MESH] |Infant[MESH] |Male[MESH] |Microspheres[MESH] |Middle Aged[MESH] |Nucleocapsid Proteins/*immunology[MESH] |Pandemics[MESH] |Phosphoproteins[MESH] |Pneumonia, Viral/*blood/diagnosis[MESH] |Sensitivity and Specificity[MESH] |Serologic Tests/*methods/standards[MESH]Improved Detection of Antibodies against SARS-CoV-2 by Microsphere-Bas(epmc).pdf DeepDyve Pubget Overpricing